Kornimate/medical-research-clean huggingface dataset:
the safety and effectiveness of ribavirin in the early stages of hiv-infection

Conditions: HIV Infections

Summary: the objective of this clinical trial is to determine whether long-term oral dosage of ribavirin delays development of symptomatic hiv disease in hiv antibody positive subjects who are completely asymptomatic (cdc classification group ii), who have only the lymphadenopathy syndrome (cdc classification group iii), or who have clinical symptoms but not severe hiv disease as defined by cdc classification, and whether the dosage regimen is safe and tolerable in these subjects.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * acyclovir. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * cdc classification group iv a (arc). * cdc classification group iv c-1 (aids) and iv c-2 (including thrush or herpes zoster during the past 2 years). positive plasma p24 antigen. * unstable medical condition, including serious cardiovascular, renal, hepatic, neurologic, infectious, or oncologic condition even if unrelated to hiv infection. * splenectomy. concurrent medication: excluded: * isoprinosine. patients with the following are excluded: * failure to give informed consent. * cdc classification group iv a (arc). * cdc classification group iv c-1 (aids) and iv c-2 (including thrush or herpes zoster during the past 2 years). positive plasma p24 antigen. * unstable medical condition, including serious cardiovascular, renal, hepatic, neurologic, infectious, or oncologic condition even if unrelated to hiv infection. * splenectomy. prior medication: excluded within 4 weeks of start of screening tests: * zidovudine. * other drug with scientifically accepted anti-hiv properties. * scientifically accepted immunostimulant treatment. * immunosuppressant. * myelosuppressant or other known toxic drugs. hiv infection group ii (cdc), asymptomatic hiv infection. * hiv antibody positive by western blot with antibodies to p24 band and gp160 band and/or gp41. two positive tests during screening will be required. cdc hiv infection group ii, asymptomatic hiv infection, as defined in appendix a, or cdc hiv infection group iii, persistent generalized lymphadenopathy (pgl, formerly las). * okt4+ lymphocyte count greater than 300 cells/mm3 and less than 600 cells/mm3. the counts will be determined on three separate evaluations separated by at least 7 days between evaluations. these three counts will be averaged and for inclusion in the study the mean of the okt4+ lymphocyte count must be greater than 200 cells/mm3 and less than 600 cells/mm3. conclusion of screening tests: * within 42 days of starting them. patients must be entered into the study within 14 days of screening completion. ability to participate as outpatient: * ambulatory, competent to sign informed consent, and able to cooperate with the treatment plan and evaluation schedule. informed consent: * must be signed before randomization to treatment. physical activity evaluation with karnofsky score greater than or equal to 90.

Keywords: ribavirin aids-related complex
clinicopathological aspects of acute appendicitis in patients above age of thirty at sulaimani emergency hospital

Conditions: Acute Appendicitis in Elderly

Summary: aims of this study are : * estimate the incidence of a.a. in patients above age of 30 y in 4 age groups . * correlate between different clinical aspects and histopathological results. * determine rate of negative appendectomy in those patients.

acute appendicitisis the clinical condition which refer to inflammation of the vermiform appendix1. it is the most common abdominal emergency2,3,4 .it accounts for more than 40,000 hospital admissions in england every year 5 . approximately 8% of the population in western countries would have appendicitis during their life 6 .in the united states, the estimated incidenc of acute appendicitis is 11 cases per 10,000 population 5 . however, in south africa, the incidencewas estimated to be less than 9 per 100,000 6 .appendectomy is considered the most common emergency surgical procedure worldwide6,8 ,9. the cause of acute appendicitis is unknown but it is multifactorial; luminal obstruction , dietary and familial factors have been suggested 5 . fecoliths are the most common cause of obstruction. it was demonstrated that the mean duration of abdominal pain in patients with gangrenous appendix is 46.2 hours and 70.9 hs for perforated 7 . the peak incidence of acute appendicitis is at the age of 10 to 30 years 6,10. there are special features for appendicitis according to age 1. a.a is primarily a disease of the younger population, with only 5-10% of cases occurring in elderly people, but the incidence of acute appendicitis in elderly began to increase with the increase in life expectancy14. older patients with acute abdominal pain are high-risk patients, unlike their younger counterparts15 . morbidity and mortality rates are greater in elderly due to atypical presentations and delay in diagnosis leading to increase rate of perforation and intra-abdominal infection.. they need to be clinically evaluated by experienced surgeons within a narrow time margin14,15.

Eligibility criteria:
inclusion criteria: * patients above age of thirty appendectomy done for them exclusion criteria: * patients less than thirty years conservative mangement

Keywords: clinico-pathology , acute appendicitis , elderly , aging , histopathology
glucagon efficiency after high and low carbohydrate diet

Conditions: Type 1 Diabetes; Hypoglycemia

Summary: no studies have investigated if the dietary composition of carbohydrate influences the glycaemic effect of single and multiple boluses of subcutaneous low-dose glucagon. further, the recommended diet composition to patients with type 1 diabetes has not been thoroughly validated. many patients with type 1 diabetes practice low carbohydrate eating patterns due to the assumption that this diet can reduce fluctuations in plasma glucose. before glucagon can be used as an add-on to intensive insulin treatment, these aspects need to be elucidated. the purpose of this study is to determine, whether diet composition of carbohydrate affects the glycogen stores in the liver and affects the glucose response of glucagon during hypoglycaemia. hypothesis: in patients with type 1 diabetes, the glucose response of a single bolus of low-dose glucagon is not associated with diet carbohydrate content. aim: the aim is to investigate how one week of high- compared to low-carbohydrate diet influence the glycaemic response of low-dose glucagon in patients with insulin pump treated type 1 diabetes. the secondary aim is to investigate how two dietary intervention weeks differ in the incidence of hypoglycaemia, postprandial hyperglycaemia, and daily glucose excursions. design:a non-blinded two-way cross-over, randomized study will be conducted. after participants have given an informed consent, they will go through four steps: 1) screening visit 2) run-in period, 3) first meal intervention for one week finalizing with one study visit and 4) second meal intervention for one week finalizing with another study visit.


Eligibility criteria:
inclusion criteria: * age 18 - 70 years * t1d ≥ 3 year * bmi 20-27 kg/m2 * csii ≥ 1 year * hba1c \< 69 mmol/mol (8.5 %) * c-peptide negative (\< 60 pmol/l) * hypoglycemia awareness (self-reported) * use of carbohydrate counting and the insulin pump bolus calculator for all meals exclusion criteria: * allergy or intolerance to lactose or glucagen®(novo nordisk, bagsværd, dk) * impaired renal function (egfr \< 60 ml/min/1.73m2) * liver disease with alat \> 2.5 times the upper limit of the reference interval * use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start * known or suspected alcohol or drug abuse * other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation * females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. * inability to understand the patient information and to give informed consent.

Keywords: glucagon carbohydrate diet
effect of yoga on postpartum depression

Conditions: Yoga

Summary: this study was conducted to investigate the effect of yoga on postpartum depression. subjects: forty primipara women with postpartum depression (ppd) selected randomly from kasr el ainy university hospital in cairo complaining of postpartum depression at least one month after childbirth shared in this study.

this study was conducted to investigate the effect of yoga on postpartum depression. subjects: forty primipara women with postpartum depression (ppd) selected randomly from kasr el ainy university hospital in cairo complaining of postpartum depression at least one month after childbirth shared in this study. group a (control group): it consisted of 20 women and treated by antidepressant drugs only for 12 weeks. group b (study group): it consisted of 20 women and treated by the same antidepressant drugs as in group a and yoga program, 50 minutes daily,7 days per week for 12 weeks (total 84 sessions).

Eligibility criteria:
inclusion criteria: * their ages were ranged from 20-35 years * their body mass index was less than 30 kg/m2 exclusion criteria: * cardiac arrhythmia, * respiratory problems, * uncontrolled type i diabetes

Keywords: yoga postpartum depression
prevention of esophageal varices by beta-adrenergic blockers

Conditions: Esophageal and Gastric Varices; Liver Cirrhosis; Portal Hypertension

Summary: the purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. cirrhosis causes an increased resistance of blood flowing through the liver. this leads to an increased pressure in the portal vein (the vein that takes blood to your liver). high portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). timolol belongs to a group of medications called beta-blockers. beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. a more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).


Eligibility criteria:
inclusion criteria: * liver biopsy compatible with cirrhosis. * absence of gastroesophageal varices. * an increased hepatic venous pressure gradient (hvpg) (6mmhg). * age over 18 and below 76 years. * informed, written consent. * absence of exclusion criteria. exclusion criteria: * presence of ascites that requires specific treatment (diuretics, paracentesis, peritoneo-venous shunt, etc). * proven hepatocellular carcinoma by radiological or histological criteria. * splenic or portal vein thrombosis by doppler-ultrasound. * presence of any concurrent disease that is expected to decrease life expectancy to less than one year. * patients taking diuretics, beta-blockers, clonidine, prazosin, nitrates, molsidomine and any drug which may have an effect on splanchnic hemodynamics/portal pressure. * patients participating in other pharmacological randomized clinical trials. * patients with primary biliary cirrhosis and primary sclerosing cholangitis will also be excluded since these entities have a slower progression of the disease, are usually enrolled in other clinical trials and are transplanted at an earlier stage. * contraindications to beta-blockers: asthma, copd with positive broncoconstrictive test, heart failure, a-v block, aortic valve stenosis, organic psychosis, insulin-dependent diabetes, hypersensitivity to beta-blockers. * women who are pregnant, nursing or of childbearing potential and who are not using oral or mechanical contraception.

Keywords: cirrhosis esophageal varices variceal hemorrhage beta-adrenergic blocker
routine versus on demand removal of the syndesmotic screw

Conditions: Anke Fracture; Syndesmotic Injury

Summary: the objective of this trial is to demonstrate that the functional outcome of 'removal on demand' of the syndesmotic screw is non-inferior compared to routine removal of the syndesmotic screw in patients with an ankle fracture.


Eligibility criteria:
inclusion criteria: * over 17 years of age * placement of a metallic syndesmotic screw for an unstable ankle fracture or an isolated syndesmotic injury * syndesmotic screw placed within two weeks of the trauma * being in such condition that one is able to possibly undergo a second procedure exclusion criteria: * iss score \>15 * injuries to the ipsi- and contralateral side which might hamper rehabilitation * other medical conditions which hamper physical rehabilitation * incomprehensive understanding of the dutch language
safety and effectiveness of 3 doses of crofelemer compared to placebo in the treatment of hiv associated diarrhea

Conditions: HIV Associated Diarrhea

Summary: this is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. this study will compare an investigational new drug (crofelemer) to placebo for the control of hiv-associated diarrhea. the first stage of the study will determine the optimal dose of study drug based on safety and response to therapy and the second stage will evaluate further the effectiveness of the optimal dose.


Eligibility criteria:
inclusion criteria: * history of hiv-1 infection confirmed by standard serological tests * stable medical regimen for treatment of hiv disease and associated conditions for at least 4 weeks prior to screening * patient-reported history of diarrhea, defined as either persistently loose stools despite regular adm use, or one or more watery bowel movements per day without regular adm use, of at least 1 month duration * colonoscopy within the past 5 years if ≥ 50 years of age. exclusion criteria: * pregnancy or breast-feeding * current or past gastrointestinal (gi) medical or surgical conditions * use of certain opiate pain medication within 2 weeks of screening * use of an antibiotic within 2 weeks prior to screening, with the exception of stable antibiotic therapy for prophylactic treatment of infection or an hiv-associated condition * cd4 counts \< 100 cells/mm3 * previous randomization into this study, or into any other crofelemer study

Keywords: hiv aids diarrhea hiv associated diarrhea
a phase i study of ibi325 in patients with advanced solid tumor

Conditions: Solid Tumor

Summary: the primary objective of this phase i study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (rp2d) of ibi325 in patients with advanced solid tumors


Eligibility criteria:
inclusion criteria: 1. histologically confirmed, locally advanced unresectable or metastatic tumors. 2. at least one evaluable or measurable lesion per recist 1.1 3. male or female subject at least 18 years old and no more than 75 years old. 4. eastern cooperative oncology group performance status (ecog ps) performance status 0 or 1. 5. must have adequate organ function 6. be able to provide archived or fresh tumor tissues- exclusion criteria: 1. previous exposure to any anti-cd73 monoclonal antibody 2. subjects participating in another interventional clinical study, except for during the survival follow-up phase of the studies. 3. unstable central nervous system netastases 4. known active autoimmune disease or inflammatory disease 5. known active infectious disease 6. other uncontrolled systematic disease that may increase the risk of participating the study-
treatment of the face and neck with lower ulthera system energy settings

Conditions: Skin Laxity

Summary: up to 60 subjects will be enrolled. enrolled subjects will receive one ulthera® treatment on the face and neck. follow-up visits will occur at 90 and 180 days post-treatment. study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

this trial is a prospective, single-site, double-blinded, randomized, split-face design. subjects will be randomized to one of three treatment groups, receiving treatment using different energy levels. global aesthetic improvement scale scores and patient satisfaction questionnaires will be obtained.

Eligibility criteria:
inclusion criteria: * male or female, age 30 to 65 years. * subject in good health. * skin laxity on the face and neck exclusion criteria: * presence of an active systemic or local skin disease that may affect wound healing. * severe solar elastosis. * excessive subcutaneous fat in the face or neck. * excessive skin laxity on the face or neck. * significant scarring in areas to be treated. * open wounds or lesions in the area to be treated. * severe or cystic acne on the area to be treated.

Keywords: ulthera® system ultherapy™ treatment ulthera, inc. ultrasound treatment for skin tightening
effectiveness of acupuncture clinical pathway

Conditions: Chronic Pain; Lumbar Back Pain; Osteoarthritis, Knee; Headache; Shoulder Pain; Cervicalgia; Musculoskeletal Pain

Summary: the study will be described the development and implementation of the clinical pathway (cpw) for acupuncture treatment in the management of patients with some chronic pain conditions. the effectiveness of this cpw will be explored in this study through retrospective analysis of clinical outcomes after administration of acupuncture treatment summarised in the guidelines.

this longitudinal, observational, retrospective study included adults (\>18 years) with common chronic pain condition treated at the son llàtzer university hospital pain clinic, in palma de mallorca, spain, from january 2015 to december 2018. all patients received treatment according to the acupuncture clinical pathway developed. the primary outcome measures will be a change in pain intensity measured by vas for pain at the completion of treatment. number of responder patients, reduction of pain medication intake, improve of quality of live scale, sleep quality index and scale of anxiety and depression after treatment are also to be included in the study. the purpose of this study is to assess the effectiveness of integrated a clinical pathway approach for chronic pain treatment with acupuncture in a pain clinic.

Eligibility criteria:
inclusion criteria: adult patients (\>18 years) acupuncture treatment for chronic pain (cervicalgia, low back pain, knee osteoarthritis, shoulder pain, headache or musculoskeletal pain), applying acupuncture treatment clinical pathway and completed at least 50% of the medical appointments. exclusion criteria: inclusion criteria: adult patients (\>18 years) acupuncture treatment for chronic pain (cervicalgia, low back pain, knee osteoarthritis, shoulder pain, headache or musculoskeletal pain), without applying acupuncture treatment clinical pathway or not completed at least 50% of the medical appointments.

Keywords: acupuncture treatment clinical pathway
clinical trial to evaluate the long-term safety of udenafil in patient with pah

Conditions: Pulmonary Arterial Hypertension

Summary: this study evaluates the long-term safety of udenafil in patient with pulmonary arterial hypertension(pah). all the patients will receive udenafil for 1-year(48-weeks).

pulmonary arterial hypertension is characterized by a progressive incerease in pulmonary vascular resistance(pvr) leading to right ventricualar failure. udenafil inhibits pde 5, an enzyme that metabolizes cgmp, enhancing the cgmp mediated relaxation and growth inhibition of vascular smooth muscle cells, including those in the lung.

Eligibility criteria:
inclusion criteria: * patients who completed the initial study(da8159_pah_ii), 12-week, double-blind, placebo-controlled trial exclusion criteria: -
post acute coronary event smoking study

Conditions: Smoking Cessation; Acute Coronary Syndrome

Summary: smoking and depressed mood are both predictive of mortality following acute coronary syndrome. however, to date, no counseling treatment has been designed to target smoking cessation and manage mood in this population. this trial will test such a treatment based on behavioral activation, an approach that has shown promise as an integrated treatment for smoking and mood management in other populations.

the occurrence of acute coronary syndrome (acs; unstable angina, st and non-st elevation myocardial infarction) can be conceptualized as a "teachable moment," whereby patients may be more receptive to smoking cessation messages. continued smoking following acs is an independent predictor of mortality. depressed mood post-acs is also predictive of mortality, and smokers with depressed mood are less likely to abstain from smoking following an acs hospitalization. thus, a single, integrated treatment that targets both depressed mood and smoking could be highly effective in reducing post-acs mortality. behavioral activation (ba) may be an ideal treatment for this population as ba can easily integrate both mood and smoking cessation related goals and it focuses on addressing restriction of valued activities, which is common in the post-acs population. thus, the overall aim of the current study is test a ba treatment manual that integrates smoking cessation and mood management for post-acs smokers (behavioral activation treatment for cardiac patients who smoke; bat-cs). we will conduct an rct (n=72) comparing bat-cs (1 in-hospital session and 5-9 post-discharge sessions) to standard care (sc; 1 in-hospital session and 5 mailed packets of printed self-help materials). differences in smoking cessation, depressed mood, and positive affect will be compared between conditions.

Eligibility criteria:
inclusion criteria: * acs diagnosis documented in medical record * smoked 3 or more cigarettes per day before being hospitalized * between the ages of 18-75 * fluent in english * regular access to a telephone * lives in the providence, ri area * willing to "strongly consider" an attempt to quit smoking at discharge exclusion criteria: * limited mental competency (i.e., mini-mental status exam \< 20) * presence of current psychosis, serious mental illness, or suicidality, expectation that patient will not live through 6 month study period * currently regularly attending counseling for depression or smoking cessation and plans to continue after discharge

Keywords: smoking mood management depression behavioral activation acute coronary syndrome myocardial infarction